Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J, Van Nieuwenhove J, Rodríguez-Barrios F, de Castro S, Velázquez S, Ceccherini-Silberstein F, De Clercq E, Camarasa MJ, Perno CF, Gago F, Balzarini J. Auwerx J, et al. FEBS Lett. 2005 Apr 25;579(11):2294-300. doi: 10.1016/j.febslet.2005.02.077. FEBS Lett. 2005. PMID: 15848161 Free article.
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
Balzarini J, Auwerx J, Rodríguez-Barrios F, Chedad A, Farkas V, Ceccherini-Silberstein F, García-Aparicio C, Velázquez S, De Clercq E, Perno CF, Camarasa MJ, Gago F. Balzarini J, et al. Mol Pharmacol. 2005 Jul;68(1):49-60. doi: 10.1124/mol.105.012435. Epub 2005 Apr 15. Mol Pharmacol. 2005. PMID: 15833734
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. Ceccherini-Silberstein F, et al. J Virol. 2005 Aug;79(16):10718-29. doi: 10.1128/JVI.79.16.10718-10729.2005. J Virol. 2005. PMID: 16051864 Free PMC article.
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.
Svicher V, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. J Virol. 2006 Jul;80(14):7186-98. doi: 10.1128/JVI.02084-05. J Virol. 2006. PMID: 16809324 Free PMC article.
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, Bertoli A, Alcaro S, Palamara G, d'Arminio Monforte A, Balzarini J, Antinori A, Lengauer T, Perno CF. Ceccherini-Silberstein F, et al. J Virol. 2007 Oct;81(20):11507-19. doi: 10.1128/JVI.00303-07. Epub 2007 Aug 8. J Virol. 2007. PMID: 17686836 Free PMC article.
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. J Infect Dis. 2008 May 15;197(10):1408-18. doi: 10.1086/587693. J Infect Dis. 2008. PMID: 18419549
323 results